LQB183 Assessment Item 2Annotated BibliographyWritten by Joseph SmithResearch QuestionIs Infleximab effective in treating the symptoms of Crohn's disease?Assignment Words: Annotated Bibliography; effective in treatmentTopic words: symptomsLimiting words: Infleximab, Crohn's disease1 Short articleSeung Lee, J. et al. (2010) Efficacy of early treatment with infliximab in pediatric Crohn's disease. World Journal of Gastroenterology, 1776-1781 DOI: 10.3748/wjg.v16.i14.1776 In this short article Seung Lee et al. explores the efficacy of early use of infliximab with maintenance and induction therapy in Crohn's disease. The study is essentially aimed at improving Infliximab which is carried out through numerous control measures by counteracting its effects with Melamine, Azathiorpine and Prednisolone. A small group of patients was divided into 3 groups A, B and C and underwent oral ingestion of the previously indicated drugs. By monitoring the activity index score over a 12- and 24-month observation period, the relapse rate would ultimately determine the drug's effectiveness. Seung Lee et al. provides general statistics that highlight the usefulness of this article by showing links between medications and their strengths and weaknesses in relation to age, time period, and health considerations. Although the study showed promising results, the article states that further experiments cannot be absolutely conclusive as there was a selection bias with a very small test group. Furthermore, the "top-down" approach used by the study is not considered a widely accepted method by medical professionals as it is still a new practice. Furthermore, the experiment is also limited by 2 years... half of the paper... A minimum of 3 induction doses was required. Patients who experienced a reduced response to infliximab were subject to a dosage increase (from 5 mg/kg to 10 mg/kg). Any evidence of worsening symptoms or related inflammation would lead to this procedure. One limitation is that the report indicates that the statistical data could have been improved if the sample size had been more varied in terms of patient medical history and number of patients observed. Chaparro suggests that increasing the dosage of infliximab is a safe and effective measure, but the effects are only short-term and patients' response is lost after a 12-month follow-up. This article can be used to demonstrate additional knowledge and general information about how the drug is used. It would be helpful to use this article as it directly relates to the efficiency of infliximabs and helps develop the topic.